We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney Transplantation.
- Authors
Seiler, Lisa K.; Phung, Ngoc Linh; Nikolin, Christoph; Immenschuh, Stephan; Erck, Christian; Kaufeld, Jessica; Haller, Hermann; Falk, Christine S.; Jonczyk, Rebecca; Lindner, Patrick; Thoms, Stefanie; Siegl, Julia; Mayer, Günter; Feederle, Regina; Blume, Cornelia A.
- Abstract
Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-membrane and the coupling of a CXCL9-binding aptamer to gold nanoparticles. LFA performance was assessed according to receiver operating characteristic (ROC) analysis. Among 15 high-scored biomarkers according to a neural network analysis, significantly higher levels of CXCL9 were found in plasma and urine and biopsy lysates of KTRs with biopsy-proven AMR. The newly developed hybrid-LFA reached a sensitivity and specificity of 71% and an AUC of 0.79 for CXCL9. This point-of-care-test (POCT) improves early diagnosis-making in AMR after Ktx, especially in KTRs with undetermined status of donor-specific HLA-antibodies.
- Subjects
BANFF (Alta.); GRAFT rejection; KIDNEY transplantation; RECEIVER operating characteristic curves; GOLD nanoparticles; APTAMERS
- Publication
Diagnostics (2075-4418), 2022, Vol 12, Issue 2, p308
- ISSN
2075-4418
- Publication type
Article
- DOI
10.3390/diagnostics12020308